


20/577512  
AP20 Rec'd PCT/PTO 27 APR 2006

PATENT  
ATTORNEY DOCKET NO. 50319/006002

Certificate of Mailing	
Date of Deposit: <u>April 27, 2006</u>	Label Number: <u>EV 919876037 US</u>
I hereby certify under 37 C.F.R. § 1.10 that this correspondence is being deposited with the United States Postal Service as "Express Mail Post Office to Addressee" with sufficient postage on the date indicated above and is addressed to Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.	
<u>Elvis De La Cruz</u>	
Printed name of person mailing correspondence	Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Francesco Bellini et al.	Confirmation No.:	Not yet assigned
Serial No.:	Not yet assigned	Art Unit:	Not yet assigned
Filed:	April 27, 2006	Examiner:	Not yet assigned
Customer No.:	21559		
Title:	Methods and Compositions for Use in Treating Diabetes		

Mail Stop PCT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the enclosed Form PTO-1449, copies of which are enclosed, with the exception of U.S. patents and U.S. patent application publications. Applicants note that European Patent No. 1 206 257 and PCT publication WO 01/15689 are in the French language. An English language abstract of the PCT publication is submitted as the required explanation as to the relevance of these documents. Also, Applicants note that the claims of the European patent are presented in the English language on page 8. Copies of search reports from a corresponding

10/577512

international application are also enclosed.

1AP20 Rec'd PCT/PTO 27 APR 2006

Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.

This statement is being filed with the application.

If there are any charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: April 27, 2006

Susan M. Michaud  
Susan M. Michaud, Ph.D.  
Reg. No. 42,885

Clark & Elbing LLP  
101 Federal Street  
Boston, MA 02110  
Telephone: 617-428-0200  
Facsimile: 617-428-7045

15201-3050110 27 APR 2006

Sheet 1 of 1

SUBSTITUTE FORM PTO-1449 (MODIFIED)  U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)  (37 C.F.R. § 1.98(b))	Attorney Docket No.	50319/006002
	Serial No.	Not yet assigned
	Applicant	Francesco Bellini et al.
	Filing Date	April 27, 2006
	Group	Not yet assigned
	IDS Filed	April 27, 2006

U.S. PATENT DOCUMENTS						
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)
	5,470,879	11/28/95	Sauvaire et al.			
	5,545,618	08/13/96	Buckley et al.			
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
	WO 01/15689	03/08/01	WIPO			
	EP1206257	11/03/04	EPO			
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)						
	Broca et al., "4-Hydroxyisoleucine: Experimental Evidence of its Insulinotropic and Antidiabetic Properties," Am. J. Physio. 277:E617-E623, 1999.					
	Broca et al., "4-Hydroxyisoleucine: Effects of Synthetic and Natural Analogues on Insulin Secretion," Eur. J. Pharmacol. 390:339-345, 2000.					
	Broca et al., "Insulinotropic Agent ID1101 (4-Hydroxyisoleucine) Activates Insulin Signaling in Rat," Am. J. Physio. Endocr. 287:E463-E471, 2004.					
	Sauvaire et al., "4-Hydroxyisoleucine: A Novel Amino Acid Potentiator of Insulin Secretion," Diabetes 47:206-210, 1998.					
	International Preliminary Report on Patentability from International Application No. PCT/CA2004/001883					
	International Search Report from International Application No. PCT/CA2004/001883					

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	